No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
NGL Fine-Chem Limited operates as a global developer and purveyor of pharmaceutical products and chemical intermediates, catering to both the animal and human health industries. The company's extensive offerings include a broad spectrum of active pharmaceutical ingredients (APIs) for veterinary use, such as diminazene aceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin. For human medical applications, they provide APIs like nitazoxanide and atovaquone. Furthermore, NGL Fine-Chem produces various intermediate compounds and specialized chemicals, alongside finished pharmaceutical preparations available in granular and tablet forms. This enterprise was founded in 1981 and has its principal operations located in Mumbai, India.
www.nglfinechem.comNo one on the platform currently holds NGLFINE.BO.
No tracked institution reports a position in NGLFINE.BO as of their last filing.
No one on the platform has traded NGLFINE.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.3% | 10.2% | 14.0% | — | — | — |
| Rev. Growth % | 36.0% | 14.2% | ||||
| Profit Margin % | 9.6% | 10.1% | 11.7% | |||
| Free Cash Flow Margin % | -10.0% | -10.0% | -5.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.0B | +5.4% | $24.25 | $24.25–$24.25 | — | 1 |
| 2028 | $1.1B | +10.0% | $22.20 | $22.20–$22.20 | — | 1 |
| 2029 | $1.5B | +35.5% | $30.35 | $30.35–$30.35 | — | 1 |
| 2030 | $1.8B | +17.4% | $38.89 | $38.89–$38.89 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| NGLFINE.BONGL Fine-Chem Limited | $2679.90 | +4.58% | $16.3B | — |
| KOPRAN.BOKopran Limited | $260.60 | +4.39% | $12.6B | — |
| KOPRAN.NSKopran Limited | $260.86 | +4.39% | $12.6B | — |
| KPL.BOKwality Pharmaceuticals Limited | $3348.05 | -2.81% | $34.7B | — |
| LINCOLN.NSLincoln Pharmaceuticals Limited | $590.70 | -1.97% | $11.8B | — |
| SAKAR.NSSakar Healthcare Limited | $1105.40 | -2.83% |
Source: Financial Modeling Prep · peers by sector/industry
| $24.3B |
| — |
| SASTASUNDR.BOHealth X Platform Limited | $307.05 | -2.80% | $9.8B | — |